Table 2 Characterization of A/AW/SC/2021 HA Monoclonal Antibodies
A(H5N1) Virus Strains | A(H5N1) mAb | |
|---|---|---|
NVX.361.4 (RBS) | NVX.73.2 (VE subdomain) | |
Pseudovirus Neutralization (IC50, ng/mL) | – | – |
A/AW/SC/22/000345-001/2021 HA | 3.571 | 42.8 |
A/Colorado/18/2022 HA | 8.497 | 79.5 |
A/Mink/Spain/3691-8 HA | 10.53 | 39.53 |
Hemagglutination Inhibition Endpoint Titers (ng/mL) | – | – |
A/AW/SC/22/000345-001/2021 HA | 250 | > 500 |
A/Colorado/18/2022 HA | 250 | > 500 |
A/Mink/Spain/3691-8 HA | 250 | > 500 |
